Trial Profile
A Prospective Study Investigating the Seminal Tenofovir Concentrations, Viral Suppression and Semen Quality in HIV-1 Infected Men after Switching Antiretroviral Therapy from TDF/FTC/EVG/COBI to TAF/FTC/EVG/COBI (Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2018
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 24 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections.